Information Provided By: 
Fly News Breaks for January 4, 2019
CEMI
Jan 4, 2019 | 07:27 EDT
Canaccord analyst Mark Massaro initiated Chembio Diagnostics with a Buy rating as he believes it is an underappreciated player in the very attractive point-of-care diagnostics space. The analyst said Chembio has best-in-class test accuracy and he likes its third party partnerships model. He also believes it can increase U.S. market share and make an even greater impact outside of the United States. Massaro has a $9 price target on Chembio Diagnostics shares.
News For CEMI From the Last 2 Days
There are no results for your query CEMI
